GlassScriptPhysician profile
Stephen J Ierardi
NPI 1548308836
$17,001.40
in general payments reported to CMS, 2019-2025
60 companies · $2,273 in 2025
The $2,273 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,470 · 2020: $1,175 · 2021: $1,943 · 2022: $4,427 · 2023: $3,000 · 2024: $2,713 · 2025: $2,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,986.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,931.04 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $2,094.87 | 2019-2025 | |
| Amgen INC. | $1,804.07 | 2019-2025 | Evenity, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,552.64 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,235.23 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $832.66 | 2021-2024 | |
| Abbott Laboratories | $616.56 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $465.86 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $412.67 | 2019-2020 | |
| Esperion Therapeutics, INC. | $393.39 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $391.08 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $374.85 | 2021-2022 | |
| Cequr Corporation | $359.89 | 2022-2024 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $284.25 | 2022-2025 | |
| Corcept Therapeutics | $270.52 | 2022-2025 | Korlym |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $265.19 | 2023-2025 | Omnipod |
| Otsuka America Pharmaceutical, INC. | $236.42 | 2022-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $206.09 | 2022-2024 | Tarpeyo |
| Janssen Pharmaceuticals, INC | $197.12 | 2019 | |
| Exact Sciences Corporation | $181.30 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $164.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $128.62 | 2022-2025 | Saphnelo, Farxiga |
| Mallinckrodt Hospital Products INC. | $123.11 | 2022-2025 | Acthar |
| Mannkind Corporation | $118.36 | 2022-2025 | Afrezza |
| Alexion Pharmaceuticals, INC. | $93.97 | 2022-2024 | Strensiq |
| Embecta Corp. | $85.55 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Ani Pharmaceuticals, INC. | $80.75 | 2025 | Purified Cortrophin Gel |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.52 | 2022-2023 | Xifaxan |
| Dexcom, INC. | $72.17 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $70.46 | 2019-2023 | Steglatro, Belsomra |
| Kyowa Kirin, INC. | $56.97 | 2023-2025 | Crysvita |
| Antares Pharma, INC. | $51.66 | 2021-2024 | Xyosted |
| Alvogen INC | $51.05 | 2022-2023 | Teriparatide |
| Xeris Pharmaceuticals, INC. | $49.85 | 2025 | Recorlev |
| Ascendis Pharma Endocrinology INC | $49.39 | 2023-2025 | Yorvipath |
| Verity Pharmaceuticals INC. | $45.31 | 2024-2025 | Tlando |
| Recordati_rare_diseases_inc. | $40.79 | 2023 | Signifor Lar, Isturisa |
| Inari Medical, INC. | $37.61 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ultragenyx Pharmaceutical INC. | $36.41 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $35.89 | 2023-2024 | Imcivree, Imcivree |
| Astellas Pharma US INC | $34.41 | 2025 | Veozah |
| Ibsa Pharma INC. | $29.71 | 2022-2023 | Tirosint, Licart |
| Tolmar, INC. | $29.26 | 2023-2025 | Jatenzo |
| Amryt Pharma Holdings LTD | $29.22 | 2022-2023 | Mycapssa |
| Chiesi USA, INC. | $26.35 | 2025 | Mycapssa |
| Amarin Pharma, INC. | $24.82 | 2022 | |
| Ascensia Diabetes Care US INC. | $23.21 | 2024 | |
| Phathom Pharmaceuticals, INC. | $22.27 | 2025 | Voquezna |
| Halozyme INC | $22.22 | 2023 | |
| Sequel Med Tech, LLC | $21.66 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $21.32 | 2022 | |
| Scpharmaceuticals INC. | $21.10 | 2025 | |
| Scilex Pharmaceuticals INC. | $20.97 | 2024 | |
| Glaxosmithkline, LLC. | $16.44 | 2023 | Shingrix, Arexvy |
| Acerus Pharmaceuticals Corporation | $15.50 | 2022 | |
| Opko Pharmaceuticals, LLC | $15.35 | 2023 | Rayaldee |
| Nabriva Therapeutics, Plc | $14.30 | 2022 | |
| Averitas Pharma INC. | $14.11 | 2025 | Qutenza |
| Kowa Pharmaceuticals America, INC. | $14.01 | 2025 | Zoryve |
| Currax Pharmaceuticals LLC | $13.08 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ierardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.